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S272 Poster Session IIMethods and Patients: Patients were adaptively randomized, based
on day SCT +30 and chimerism status: Arm I Clo:Flu 10:30 mg/m2,
Arm II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV Clo at
40 mg/m2. The NA were/was infused over 60 min each once daily
for 4 d; then Bu was infused over 3 hrs to an average daily AUC of
6,000 mM-min. GVHD-prophylaxis was tacrolimus and mini-
MTX. Recipients of unrelated or one antig-mism related donor cells
received rabbit-ATG.
Results: 41 pts were enrolled, M:F 24:17, median age 45 yrs (range:
6-59). 32 pts had AML (ind. failure: 12, chemotherapy refr. relapse:
8, untreated relapse: 2, CR2 + CR2 p: 6, high-risk CR1: 1 [cytog. -7
and t(3;12)]). 17 of the 32 AML pts had intermediate, 15 had poor
prognosis cytogenetics. 9 pts had CML (BC: 2, second AP: 3, and
late CP: 4). Donors were 51% related; stem cell source was 61%
bone marrow or 39% peripheral blood.
All 41 pts engrafted. Peripheral blood (T-cell) chimerism at day
+30 revealed Arms I + II to have a median of 85% donor-derived
DNA, and Arms III + IV 100% donor-DNA; at day +100 all cohorts
had 100% donor-DNA.There were no secondary graft failures. Due
to the adaptive randomization, most pts were gradually allocated to
Arm III. 19 of the 23 pts with active AML and 7 of the 9 CML pts
enteredCR after SCT.We had 2 treatment-related deaths in the first
100 d (1 pneumonia and 1 GVHD). Grade 2-3 mucositis occurred in
about half the pts, but there were no serious toxicities. The median
follow-up is 16 months; one-year overall and event-free survival
are 52 and 40%, respectively.
Conclusions: 1) [Clo6 Flu] + IV Bu-based conditioning therapy is
safe and efficacious in high-risk pts withML/MDS. 2) The immuno-
suppressive capability of Clo allows its use in pretransplant condi-
tioning. 3) The in vitro studies which showed a superior
cytotoxicity of [Clo + Flu + Bu] than either [Clo + Bu] or [Flu + Bu]
were supported clinically by the better clinical outcomes in Arm
III. Additional pts and longer follow-up are needed to fully evaluate
the efficacy of [Clo + Flu + Bu] in pre-transplant conditioning.307
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Allogeneic hematopoietic cell transplantation (HCT) following
conditioning with total lymphoid irradiation (TLI) and antithymo-
cyte globulin (ATG) is an effective treatment modality for leukemia
and lymphoma.We recently reported 3-year event-free survival rates
for AML and NHL of 40% and 42%, respectively (Kohrt et al.,
Blood, 114:1099-1109). Disease relapse remains the primary cause
of treatment failure, thus the ability to predict when patients are at
risk for relapse would allow for timely immunologic interventions,
such as alterations of immunosuppressive therapy or donor lympho-
cyte infusions.We analyzed CD3/15/19/56 peripheral blood chime-
rism in 122 patients who underwent allo-HCT after TLI-ATG
conditioning between December 2001 and July 2009. Univariate
analysis comparing complete chimerism (.95% donor CD3) to
mixed chimerism (5-95% donor CD3) did not reliably predict events
(relapse or death). Several methods of evaluating the predictive value
of subset chimerism were then assessed, including Cox regression
analysis of chimerism trajectory, receiver operator characteristic
(ROC) analysis of chimerism trajectory, and ROC analysis of indi-
vidual chimerism measurements at days 90, 120, 150, and 180 after
HCT. Although subset chimerism generally performed poorly as
a predictor of outcome with all analytic strategies, ROC analysis of
chimerism trajectory and individual measurements demonstrated
limited utility for predicting event-free survival. We calculated the
area under the ROC curve (AUC), which represents the probability
that a randomly chosen patient with an observed event has lower chi-
merism than a randomly chosen patient without an observed event.
An AUC greater than 80% represents a high likelihood of event pre-
diction. For patients with lymphoid malignancies, all subsets ex-
hibited poor predictive value using all methods, and with ROC
analysis the AUC was uniformly less than 70% for all subset-time-point combinations. In patients with myeloid malignancies, only
CD15 chimerism was predictive of event-free survival, with AUC
values of 84% at day 90, 79% at day 120, 82% at day 150 and 88%
at day 180. We conclude that subset donor chimerism has little util-
ity for predicting event-free survival in lymphoid malignancies, and
that only CD15 chimerism predicts outcome in myeloid malignan-
cies. Additional patient characteristics will need to be incorporated
into the decision to apply immunological therapies to alter outcome
after non-myeloablative HCT.308
LOW CD4 T-LYMPHOCYTE REACTIVITY BY THE CYLEX IMMUKNOW AS-
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Viral infections are a significant cause ofmorbidity after allogeneic
stem cell transplantation. Modifying intensity of immunosuppres-
sion according to immune function may reduce infections. Cur-
rently, no routine functional assays to monitor immune function of
the new graft exist. The Cylex ImmuKnow assay is a FDA approved
test that quantifies cellular immune function by measuring intracel-
lular ATP activity released by PHA-stimulated CD4 T cells in
blood, and has correlated with solid organ graft outcomes.
We correlated ATP activity with viral infections in the first 100
days post-transplant. 341 blood samples were collected q1-3 weeks
from 32 patients of median age 42 (21-59) years undergoing related
(14) or unrelated (18) donor transplants. All received myeloablative
doses of chemotherapy6TBI, with ATG in 14 patients. GvHDpro-
phylaxis included FK506 with sirolimus (28) or methotrexate (4).
CMV and EBV load was monitored in plasma by PCR q1-2 weeks
and preemptive therapy started on reactivation with other viral test-
ing as clinically indicated. 14 patients developed infections while on
GvHD prophylaxis, including CMV (10), EBV (3), BK hemorrhagic
cystitis (8), adenovirus gastritis (1), and HSV pneumonitis (1).
Baseline median ATP activity for all patients was 280 (5-809) ng/
ml, compared to 491 (238-842) ng/ml for healthy volunteers
(P\0.0001). ATP activity only modestly correlated with lympho-
cyte (R25 0.21) and WBC (R25 0.45) counts. Median ATP activi-
ties were lower for patients who developed infections between days
+31 and +60 (31 vs 106 ng/ml, P5 0.0007), and days +61 and +100
(34 vs 139 ng/ml, P5 0.0006). On logistic regression, low ATP ac-
tivity was predictive of infections (P\0.0001), but lymphocyte and
WBC counts were not. Using 90 ng/ml as cutoff, 11 of 20 patients
with ATP activity\100 ng/ml developed infections compared to 1
of 12 with activity $100 ng/ml between days +31 and +60
(P5 0.01). Between days +60 and +100, 9 of 12 patients with levels
\90 ng/ml developed infections, compared to 1 of 14 patients with
levels $90 ng/ml (P5 0.001). Median ATP activity was 251 (97-
494) ng/ml at the onset of grade 2-4 acute GvHD that occurred in
4 patients. Our results indicate that low ATP activity in CD4 T cells
is strongly predictive of viral infections in the first 100 days after
transplant, and suggest that modifying the intensity of immunosup-
pression to maintain ATP activity around 90 ng/ml should be inves-
tigated as a strategy to reduce infections.309
AZITHROMYCIN FOR BRONCHIOLITIS OBLITERANS FOLLOWING ALLO-
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Background: Bronchiolitis obliterans (BO) following HSCT is as-
sociated with significant morbidity and mortality with few effective
